Literature DB >> 3659245

Intramedullary spinal cord metastases: a clinical and pathological study of nine cases.

J W Dunne1, C G Harper, R Pamphlett.   

Abstract

The clinical and pathological findings in nine cases of intramedullary spinal cord metastases are reported and are compared with those of previous studies. Intramedullary metastases are more common than is generally believed and the incidence is probably increasing with the more prolonged survival of cancer patients. A wide spectrum of symptoms and signs may be produced, frequently with attendant diagnostic difficulties. Most patients present with myelopathy as the first manifestation of cancer or of its recurrence. Symptoms may be present for several months, with few clinical signs, despite distortion and destruction of much of the spinal cord by tumour. The extent of metastatic disease remains limited in a significant proportion of patients. No neurological symptoms or signs differentiate intramedullary metastases clearly from the more common extradural deposits. However, the diagnosis should be considered when myelopathy evolves more slowly, where plain radiographic evidence of adjacent vertebral disease is absent, and particularly when myelography is normal. Early diagnosis and aggressive medical treatment may provide for a more favourable outcome.

Entities:  

Mesh:

Year:  1986        PMID: 3659245

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  11 in total

Review 1.  Intramedullary spinal cord metastases in breast cancer: report of four cases and review of the literature.

Authors:  Christos Kosmas; Maria Koumpou; Maria Nikolaou; John Katselis; Georgia Soukouli; Nina Markoutsaki; Vassiliki Kostopoulou; Assimina Gaglia; Nikolaos Mylonakis; Athanassios Karabelis; Dimitrios Pectasides
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

Review 2.  Metastasis to nervous system: spinal epidural and intramedullary metastases.

Authors:  Melike Mut; David Schiff; Mark E Shaffrey
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

3.  Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone.

Authors:  B P O'Neill; T M Habermann; T E Witzig; M Rodriguez
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

Review 4.  Chemotherapy for intramedullary spinal cord tumors.

Authors:  C Balmaceda
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

5.  Surgical treatment of intramedullary spinal cord metastases of systemic cancer: functional outcome and prognosis.

Authors:  T Gasser; I E Sandalcioglu; B El Hamalawi; J A P van de Nes; D Stolke; H Wiedemayer
Journal:  J Neurooncol       Date:  2005-06       Impact factor: 4.130

6.  Intramedullary Spinal Cord Metastases from Differentiated Thyroid Cancer, a Case Report.

Authors:  Fabio Volpe; Leandra Piscopo; Mariarosaria Manganelli; Maria Falzarano; Federica Volpicelli; Carmela Nappi; Massimo Imbriaco; Alberto Cuocolo; Michele Klain
Journal:  Life (Basel)       Date:  2022-06-09

Review 7.  CNS complications of breast cancer: current and emerging treatment options.

Authors:  Evert C A Kaal; Charles J Vecht
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

8.  A case report of "spinal cord apoplexy" elicited by metastatic intramedullary thyroid carcinoma.

Authors:  In Jae Choi; Jae Chil Chang; Dong Won Kim; Gun Choi
Journal:  J Korean Neurosurg Soc       Date:  2012-04-30

9.  Intramedullary spinal cord metastases: a single-institution experience.

Authors:  Sung Sook Lee; Min Kyoung Kim; Sun Jin Sym; Sang Wee Kim; Woo Kun Kim; Sung-Bae Kim; Jin-Hee Ahn
Journal:  J Neurooncol       Date:  2007-02-20       Impact factor: 4.506

10.  Intramedullary spinal cord metastasis in renal cell carcinoma: a case report of the surgical experience.

Authors:  Jeongill Park; Seok-Won Chung; Kyoung-Tae Kim; Dae-Chul Cho; Jeong-Hyun Hwang; Joo-Kyung Sung; Dakeun Lee
Journal:  J Korean Med Sci       Date:  2013-07-31       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.